MAINZ BIOMED N.V.
Data quality: 100%
QUCY
Nasdaq
Manufacturing
Chemicals
$0.48
▼
$0.04
(-7.71%)
Mkt Cap: 6.00 M
Price
$0.48
Mkt Cap
6.00 M
Day Range
$0.46 — $0.52
52-Week Range
$0.40 — $4.43
Volume
545,616
Open $0.50
50D / 200D Avg
$0.77
37.65% below
50D / 200D Avg
$1.29
62.94% below
Quick Summary
Key Takeaways
Negative free cash flow of -10.98 M
Capital efficient — spends only 0.23% of revenue on capex
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-2526.61%
Below sector avg (-51.02%)
ROIC-492.09%
Net Margin-3018.31%
Op. Margin-3004.97%
Safety
Debt / Equity
1.49
Above sector avg (0.33)
Current Ratio0.50
Interest Coverage-43.22
Valuation
PE (TTM)
-0.37
Above sector avg (-1.98)
P/B Ratio9.35
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (44 peers)
Peer Comparison
vs Manufacturing sector median (44 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -0.4 | -2.0 |
| P/B | 9.4 | 5.1 |
| ROE % | -2526.6 | -51.0 |
| Net Margin % | -3018.3 | -150.2 |
| Rev Growth 5Y % | — | 9.3 |
| D/E | 1.5 | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 537,080.0 | Net Income (TTM) | -16.21 M |
| ROE | -2526.61% | ROA | -304.29% |
| Gross Margin | 72.58% | Operating Margin | -3004.97% |
| Net Margin | -3018.31% | Free Cash Flow (TTM) | -10.98 M |
| ROIC | -492.09% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 1.49 | Current Ratio | 0.50 |
| Interest Coverage | -43.22 | Asset Turnover | 0.10 |
| Working Capital | -1.85 M | Tangible Book Value | -471,824 |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.37 | Forward P/E | N/A |
| P/B Ratio | 9.35 | P/S Ratio | 11.17 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -183.06% | ||
| Market Cap | 6.00 M | Enterprise Value | 6.96 M |
| Per Share | |||
| EPS (Diluted TTM) | -2.70 | Revenue / Share | 0.04 |
| FCF / Share | -0.88 | OCF / Share | -0.88 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 0.23% | FCF Conversion | 67.74% |
| SBC-Adj. FCF | -12.45 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 |
|---|---|
| Revenue | 537,080.0 |
| Net Income | -16.21 M |
| EPS (Diluted) | -2.70 |
| Gross Profit | 389,792.0 |
| Operating Income | -16.14 M |
| EBITDA | — |
| R&D Expenses | 4.91 M |
| SG&A Expenses | — |
| D&A | 615,720.0 |
| Interest Expense | 373,458.0 |
| Income Tax | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 |
|---|---|
| Total Assets | 5.33 M |
| Total Liabilities | 4.69 M |
| Shareholders' Equity | 641,600.0 |
| Total Debt | 956,902.0 |
| Cash & Equivalents | — |
| Current Assets | 1.84 M |
| Current Liabilities | 3.69 M |
{"event":"ticker_viewed","properties":{"ticker":"QUCY","listing_kind":"stock","pathname":"/stocks/qucy","exchange":"Nasdaq","country":"US"}}